z-logo
Premium
Clinical significance of isolated tumor cells and micrometastasis in low‐grade, stage I endometrial cancer
Author(s) -
Piedimonte Sabrina,
Richer Lara,
Souhami Luis,
Arseneau Jocelyne,
Fu Lili,
Gilbert Lucy,
Alfieri Joanne,
Jardon Kris,
Zeng Xing Ziggy
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25259
Subject(s) - medicine , endometrial cancer , micrometastasis , lymphovascular invasion , stage (stratigraphy) , lymph node , oncology , urology , lung cancer , gastroenterology , adjuvant therapy , cancer , metastasis , paleontology , biology
Ultrastaging in endometrial cancer (EC) led to increased detection of isolated tumor cells (ITC, ≤0.2 mm) and micrometastases (MM, 0.2‐2 mm), with unclear effect on prognosis. Our aim was to characterize the impact of ITC and MM on the outcome of these patients. Methods Grade 1 to 2 stage I endometrioid EC patients with nodal ITC ( n  = 11) or MM ( n  = 12) between 2012 and 2018 were retrospectively compared to a matched group of lymph node negative ( n  = 18) patients based on age, body mass index, grade, myometrial invasion, and lymphovascular space invasion (LVI) status using propensity score analysis (1:1). Mann‐Whitney U tests were performed on continuous variables and χ 2 tests on categorical variables. Progression‐free survival (PFS) was the main endpoint. Results All MM and 81% of ITC had LVI. More ITC/MM patients received RT and chemotherapy (91.7% vs 18.4%; 70.8% vs 4.5%, respectively; P  < 0.01) without significant difference in treatment‐related toxicities (25% vs 27.3% grade 1%‐2% and 20.8% vs 9.1% grade 2‐3; P  = 0.538) or PFS (29.2 vs 25 months; P  = 0.828). Two distant recurrences occurred in MM patients after 2.5 years; one lung and one para‐aortic lymph node. Conclusion With adjuvant treatment, ITC/MM in otherwise well‐differentiated stage I endometrial cancer have similar outcomes to matched LN− patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom